Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study
Open Access
- 11 November 2008
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 143 (5), 707-715
- https://doi.org/10.1111/j.1365-2141.2008.07294.x
Abstract
This study evaluated the efficacy and safety of imatinib in chronic eosinophilic leukaemia (CEL, n = 23) and hypereosinophilic syndrome (HES, n = 13). In CEL with FIP1L1‐PDGFRA (n = 16) or various PDGFRB fusion genes (n = 5), complete haematological remission (CHR) was achieved in 95% (20/21) after 3 months. Complete molecular remission (CMR) was seen in 75% (12/16) of cases with FIP1L1‐PDGFRA positive CEL by 6 months, and in 87% (13/15) after 12 months. CMR was achieved in three of five PDGFRB fusion positive patients after 3, 9 and 18 months respectively. All patients are currently on imatinib (100 mg; n = 13, 400 mg; n = 8) and no molecular relapse has yet been observed (median 26·7 months; range, 6·9–39·9). Imatinib was less effective in HES and CEL without known molecular aberration (n = 15); CHR was observed in 40% (6/15) of patients, two patients relapsed after 4·8 and 24·5 months. Three patients died due to imatinib‐resistant progressive CEL (n = 2) or myocardial infarction (n = 1) unrelated to study treatment. Overall, imatinib was well tolerated with a low incidence of grade III/IV toxicities. These data confirmed the long‐term efficacy of imatinib for PDGFR‐rearranged CEL patients, and also showed that a minority of HES cases without known molecular aberrations may benefit from imatinib.Keywords
This publication has 23 references indexed in Scilit:
- The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR -positive hypereosinophilic syndrome. Results of a multicenter prospective studyHaematologica, 2007
- Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemiaBlood, 2007
- Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapyBest Practice & Research Clinical Haematology, 2006
- Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disordersBlood, 2006
- The results of imatinib therapy for patients with primary eosinophilic disordersEuropean Journal of Haematology, 2006
- Beyond chronic myelogenous leukemiaCancer, 2004
- Practical Management of Patients With Chronic Myeloid Leukemia Receiving ImatinibJournal of Clinical Oncology, 2003
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeThe New England Journal of Medicine, 2003
- Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor BetaThe New England Journal of Medicine, 2002
- THE HYPEREOSINOPHILIC SYNDROMEMedicine, 1975